Worth reading
66In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
1750000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the 11th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Who receives how much1,750,000Shares
Shares delivered during the month: 1,750,000 new shares (transferred treasury shares: not stated)
EVO FUND (issued on 26 December 2025; this disclosure covers monthly exercise status)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
2.3% (exercise ratio under the exercise restrictions; 1,750,000 shares delivered during the month / 75,355,233 listed shares outstanding at the time of issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The exercise price in May 2026 was ¥31–¥37 per share. Details of the adjustment clause and the floor price: not disclosed
Number of Stock Acquisition Rights
Total issued: 700,000 rights; exercised during the month: 17,500 rights; unexercised at the end of the preceding month: 588,000 rights; unexercised at month-end: 570,500 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments
Most recent equity financing
26 December 2025: Issuance of the 11th Stock Acquisition Rights, with EVO FUND as the allottee (700,000 rights issued)
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the 11th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 1,750,000 new shares (transferred treasury shares: not stated) |
| Intended allottee | EVO FUND (issued on 26 December 2025; this disclosure covers monthly exercise status) |
| Dilution Rate | 2.3% (exercise ratio under the exercise restrictions; 1,750,000 shares delivered during the month / 75,355,233 listed shares outstanding at the time of issuance) |
| Total number of issued shares | 86,555,233 shares (as of the end of the month preceding the relevant month) → Not disclosed |
| Exercise price | The exercise price in May 2026 was ¥31–¥37 per share. Details of the adjustment clause and the floor price: not disclosed |
| Number of Stock Acquisition Rights | Total issued: 700,000 rights; exercised during the month: 17,500 rights; unexercised at the end of the preceding month: 588,000 rights; unexercised at month-end: 570,500 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments |
| Most recent equity financing | 26 December 2025: Issuance of the 11th Stock Acquisition Rights, with EVO FUND as the allottee (700,000 rights issued) |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is a report on the monthly exercise status, and the company has provided no explanation of the reasons for the exercises.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.